Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland

Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland Am J Cardiovasc Drugs 2006; 6 (5): 349-355 ORIGINAL RESEARCH ARTICLE 1175-3277/06/0005-0349/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland The National FINRISK Study 1 1 2 3 3,4 Evo Alemao, Don Yin, Harri Sintonen, Veikko Salomaa and Pekka Jousilahti 1 Outcomes Research, Merck and Co., Inc., Whitehouse Station, New Jersey, USA 2 Department of Public Health, University of Helsinki, Helsinki, Finland 3 Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland 4 School of Public Health, University of Tampere, Tampere, Finland Abstract Background: European and US study findings show that patients in primary care and specialty care are not adequately treated for cholesterol reduction. Objective: To evaluate lipid-lowering treatment in Finland, estimate the proportions of subjects who are achieving cholesterol goals, and assess the influence of determinants on goal attainment. Methods: Subgroup analysis of the FINRISK study, a national study of cardiovascular disease risk factors in Finland. Study participants, the subgroup of patients on lipid-lowering therapy from FINRISK, completed a postal self-administered questionnaire on health/health behavioral factors. Serum total cholesterol (TC) and other clinical variables were measured using a standardized protocol. Ten-year coronary risk http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland

Loading next page...
 
/lp/springer-journals/evaluation-of-lipid-lowering-therapy-and-cholesterol-goal-attainment-oApVDZm14P

References (51)

Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200606050-00008
pmid
17083270
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2006; 6 (5): 349-355 ORIGINAL RESEARCH ARTICLE 1175-3277/06/0005-0349/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland The National FINRISK Study 1 1 2 3 3,4 Evo Alemao, Don Yin, Harri Sintonen, Veikko Salomaa and Pekka Jousilahti 1 Outcomes Research, Merck and Co., Inc., Whitehouse Station, New Jersey, USA 2 Department of Public Health, University of Helsinki, Helsinki, Finland 3 Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland 4 School of Public Health, University of Tampere, Tampere, Finland Abstract Background: European and US study findings show that patients in primary care and specialty care are not adequately treated for cholesterol reduction. Objective: To evaluate lipid-lowering treatment in Finland, estimate the proportions of subjects who are achieving cholesterol goals, and assess the influence of determinants on goal attainment. Methods: Subgroup analysis of the FINRISK study, a national study of cardiovascular disease risk factors in Finland. Study participants, the subgroup of patients on lipid-lowering therapy from FINRISK, completed a postal self-administered questionnaire on health/health behavioral factors. Serum total cholesterol (TC) and other clinical variables were measured using a standardized protocol. Ten-year coronary risk

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Aug 20, 2012

There are no references for this article.